Cefodizime has been shown to be generally well tolerated in drug trials and its adverse effects are mainly gastrointestinal or dermatological. Gastrointestinal adverse effects were observed in 2.4% of patients during clinical trials and included: diarrhea, nausea, vomiting, and elevated transaminases. Allergic symptoms were observed in 1.1% of patients and include: [[exanthema]], [[urticaria]], and [[pruritus]]. Other adverse effects observed include local site reactions, pain at site of injection, and [[phlebitis]].<ref name=Barradell />

 

